Neumarker uses AI to analyze multimodal brain data—such as neuroimaging, EEG, proteomics, and digital phenotyping—to discover and validate objective biomarkers for CNS disorders. Its cloud‑based platform delivers risk scores, disease staging, and treatment‑response predictions to clinicians and provides quantitative endpoints for pharmaceutical trial design and patient stratification.
Funding
Funding not disclosed
Founders
Product
Problem
Current mental health and CNS disease management relies on subjective assessments and limited physiological measures, leading to trial‑and‑error treatment selection and high rates of ineffective therapy. Drug development for CNS disorders suffers from low success rates, long timelines, and strong placebo effects due to the absence of objective, quantifiable biomarkers.
Solution
Neumarker applies artificial‑intelligence algorithms to large multimodal datasets (e.g., neuroimaging, electrophysiology, proteomics, and behavioral metrics) to discover and validate objective biomarkers of CNS pathology and treatment response. These biomarkers are delivered through a cloud‑based analytics platform that provides clinicians with actionable risk scores and treatment‑matching recommendations, and supplies pharmaceutical developers with quantitative endpoints for trial design and patient stratification. By translating complex brain function into measurable signals, Neumarker aims to reduce diagnostic uncertainty, accelerate therapeutic decision‑making, and improve the efficiency of CNS drug development pipelines.
Target Audience
Primary customers are mental‑health clinicians and neurologists seeking objective diagnostic tools, and pharmaceutical companies developing CNS therapeutics that require reliable biomarkers for patient selection and efficacy assessment.
Features
- AI‑driven discovery pipeline that integrates neuroimaging, EEG, CSF proteomics, and digital phenotyping to generate composite biomarkers
- Validated biomarker panels for major CNS disorders such as Alzheimer’s disease, major depressive disorder, schizophrenia, epilepsy, and addiction
- Cloud‑hosted analytics dashboard delivering risk scores, disease staging, and predicted treatment response for individual patients
- API and data export tools enabling seamless incorporation of biomarker outputs into electronic health records and clinical trial data management systems
- Continuous learning framework that updates biomarker models as new patient data and trial results become available